PE firms Circle Merck’s Generics

Merck KGaA is expecting at least two bids for its generic drugs business, according to The Financial Times Deutscheland. Apax Partners and Bain Capital have teamed up, while another group includes KKR and Warburg Pincus. The Carlyle Group also is considering a bid, while earlier reports indicated interest from Cinven, Permira and TPG. The final sale price is expected to be between Euro 4 billion and Euro 5.5 billion.